Navigation Links
Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)

JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (, a developer of oral delivery systems, announced today that it has been selected to display its abstract, entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects, at the upcoming 68th Annual American Diabetes Association's Scientific Sessions Conference in San Francisco, highlighting the successful results from its oral insulin trials on healthy volunteers.

The abstract will also be printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal Diabetes.

Oramed's technology will be included in an oral presentation by Prof. Dr. Lutz Heinemann, CEO of Profil Institute for Metabolic Research, "Pharmacokinetics and Pharmacodynamics of Alternate Insulin Delivery Systems," on Saturday, June 7, 2008 from 4 pm to 6 pm.

"The selection of Oramed as one of the companies to exhibit at Scientific Sessions is a great opportunity that allows us to present our data from human trials to the leading scientists in the diabetes field from all over the world," said Nadav Kidron, Oramed CEO.

Oramed's abstract poster has been assigned presentation number 425-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Saturday, June 7 from 6-7PM and from 12-2PM on Monday, June 9 at San Francisco's Moscone Convention Center, Hall D.

For more information about the ADA and the upcoming conference, please visit

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals,

Eric Rosenberg,

Cell: +972-54-566-7713,

Office: +972-2-566-0001,

Email: .

Media Contacts:

Ruder Finn Israel for Oramed,

Matthew Krieger,

Cell: +972-54-467-6950,

Office: +972-2-589-2003,

Email: .

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
3. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
4. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
5. VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
8. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
9. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
10. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
11. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Post Your Comments:
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):